OverviewSuggest Edit

Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). The Company is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.
TypePublic
Founded2002
HQStoughton, MA, US
Websitecollegiumpharma.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2019)255(-4%)
Job Openings2
Revenue (FY, 2020)$310 M(+5%)
Share Price (May 2021)$21.8(-1%)
Cybersecurity ratingBMore

Key People/Management at Collegium Pharmaceutical

Michael Heffernan

Michael Heffernan

Co - Founder, President & CEO
Michael Heffernan

Michael Heffernan

Co-Founder, President, CEO
Heow Tan

Heow Tan

Vice President of Technical Operations
Show more

Collegium Pharmaceutical Office Locations

Collegium Pharmaceutical has an office in Stoughton
Stoughton, MA, US (HQ)
100 Technology Center Dr #300
Show all (1)

Collegium Pharmaceutical Financials and Metrics

Collegium Pharmaceutical Revenue

Collegium Pharmaceutical's revenue was reported to be $310.02 m in FY, 2020
USD

Revenue (Q1, 2021)

87.7m

Gross profit (Q1, 2021)

55.6m

Gross profit margin (Q1, 2021), %

63.4%

Net income (Q1, 2021)

15.7m

EBIT (Q1, 2021)

21.2m

Market capitalization (12-May-2021)

768.9m

Closing stock price (12-May-2021)

21.8

Cash (31-Mar-2021)

182.8m

EV

595.1m
Collegium Pharmaceutical's current market capitalization is $768.9 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.7m28.5m280.4m296.7m310.0m

Cost of goods sold

213.0k2.6m165.7m193.7m130.2m

Gross profit

1.5m25.9m114.7m103.0m179.8m

Gross profit Margin, %

88%91%41%35%58%
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

408.0k2.2m3.6m12.0m63.7m73.1m70.2m74.5m75.0m72.9m76.5m78.1m79.2m87.7m

Cost of goods sold

29.0k371.0k577.0k553.0k43.1m46.8m46.0m49.2m48.7m46.8m37.5m29.7m31.0m32.1m

Gross profit

379.0k1.8m3.0m11.4m20.6m26.2m24.2m25.4m26.4m26.2m39.0m48.4m48.2m55.6m

Gross profit Margin, %

93%83%84%95%32%36%34%34%35%36%51%62%61%63%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

95.7m153.2m118.7m146.6m170.0m174.1m

Accounts Receivable

2.1m10.0m77.9m73.0m83.3m

Prepaid Expenses

3.0m5.1m3.1m4.8m

Inventories

1.2m1.9m1.8m7.8m9.6m15.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(27.3m)(94.2m)(74.9m)(39.1m)(22.7m)26.8m

Depreciation and Amortization

171.0k655.0k594.0k110.9m15.5m61.6m

Inventories

(659.0k)(1.3m)(497.0k)219.0k(1.8m)(8.3m)

Accounts Payable

1.3m5.6m(3.4m)6.5m(5.9m)3.8m
USDQ1, 2015

Financial Leverage

-0.6 x
Show all financial metrics

Collegium Pharmaceutical Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Collegium Pharmaceutical Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Collegium Pharmaceutical Online and Social Media Presence

Embed Graph

Collegium Pharmaceutical News and Updates

Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering

STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000 aggregate principal amount of convertible senior notes due 2026 (the “notes”) in a public offering register…

Collegium Pharmaceutical Blogs

Collegium Reports Record Quarterly Revenue of $87.7 Million

– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 – – Nucynta ® Franchise and Adjusted EBITDA 2021 Guidance Range Raised   – – Colleen Tupper Appointed as Next CFO;  Paul Brannelly will be Leaving the Company to Pursue Other Opportunities   – –

Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update

Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update Content Import Thu, 04/15/2021 - 16:01 Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update April 15, 2021…

Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million

Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million Content Import Thu, 02/25/2021 - 16:03 Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million February 25, 2021 at 4:01 PM EST This release is a backfill from a News Wire …

Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update

STOUGHTON, Mass. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time . The Company will discuss its financial results and

Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020

Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020 Content Import Thu, 11/05/2020 - 16:02 Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020 November 5, 2020 at 4:01 PM EST This release is a backfill from a News …

Collegium Announces Publication of “Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza® ER” in Pain Medicine

Collegium Announces Publication of “Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza® ER” in Pain Medicine Content Import Mon, 10/26/2020 - 08:02 Collegium Announces Publication of “Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza® ER” in Pain Medicine …
Show more

Collegium Pharmaceutical Frequently Asked Questions

  • When was Collegium Pharmaceutical founded?

    Collegium Pharmaceutical was founded in 2002.

  • Who are Collegium Pharmaceutical key executives?

    Collegium Pharmaceutical's key executives are Michael Heffernan, Michael Heffernan and Heow Tan.

  • How many employees does Collegium Pharmaceutical have?

    Collegium Pharmaceutical has 255 employees.

  • What is Collegium Pharmaceutical revenue?

    Latest Collegium Pharmaceutical annual revenue is $310 m.

  • What is Collegium Pharmaceutical revenue per employee?

    Latest Collegium Pharmaceutical revenue per employee is $1.2 m.

  • Who are Collegium Pharmaceutical competitors?

    Competitors of Collegium Pharmaceutical include Assertio Therapeutics, Jacobson Pharma and Hanmi Pharmaceutical.

  • Where is Collegium Pharmaceutical headquarters?

    Collegium Pharmaceutical headquarters is located at 100 Technology Center Dr #300, Stoughton.

  • Where are Collegium Pharmaceutical offices?

    Collegium Pharmaceutical has an office in Stoughton.

  • How many offices does Collegium Pharmaceutical have?

    Collegium Pharmaceutical has 1 office.